Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study
Josie Hayes(University of California, Berkeley), Eric B. Haura(Moffitt Cancer Center), Judy S. Wang(Sarah Cannon), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Martha Guerra(Revolution Medicines (United States)), Richa Dua(Revolution Medicines (United States)), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Pasi A. Jänne(Harvard University), Michael S. Gordon(Pinnacle Oncology Hematology), Howard A. Burris(Deaconess Hospital), Jonathan W. Riess(University of California Davis Medical Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Xiaolin Wang(Macau University of Science and Technology), Hongfang Wang(Memorial Sloan Kettering Cancer Center), Jose M. Pacheco(University of Colorado Cancer Center), Anna Capasso(The University of Texas at Austin), Bojena Bitman(Revolution Medicines (United States)), Ariel Chen(Revolution Medicines (United States)), Marianna Koczywas(City Of Hope National Medical Center)
Cited by 4
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k